New research spearheaded by scientists at the Seaver Autism Center for Research and Treatment at Mount Sinai has dramatically revised previous estimates for the prevalence of Phelan-McDermid syndrome (PMS), suggesting the rare genetic disorder may be significantly more common than initially believed. The groundbreaking findings, published in the esteemed journal Autism Research, indicate that PMS could affect approximately 1 in every 7,300 individuals, a figure that could translate to tens of thousands of undiagnosed people in the United States alone. This revised understanding carries profound implications for diagnosis, research, and the development of targeted therapies.
A Deeper Look at Phelan-McDermid Syndrome
Phelan-McDermid syndrome is a complex genetic condition characterized by a deletion or mutation primarily involving the SHANK3 gene, located on chromosome 22. This genetic anomaly can manifest in a wide spectrum of medical, intellectual, and behavioral challenges. A significant majority of individuals diagnosed with PMS also meet the diagnostic criteria for autism spectrum disorder (ASD). Indeed, alterations in the SHANK3 gene are now understood to be a contributing factor in as many as one percent of all diagnosed cases of autism spectrum disorder.
The syndrome’s diverse presentation makes it challenging to identify. Symptoms can range from developmental delays, intellectual disability, and speech impairments to hypotonia (low muscle tone), epilepsy, gastrointestinal issues, and behavioral differences. The variability in these manifestations, coupled with potential limitations in historical genetic testing capabilities, has likely contributed to a substantial underdiagnosis of PMS.
Unveiling a Larger Population Through Comprehensive Genetic Data
To arrive at their revised prevalence estimate, the Mount Sinai research team embarked on an ambitious project, collaborating with a wide array of stakeholders in the genetic testing and autism research landscape. This collaborative effort involved pooling data from numerous genetic testing laboratories, leading academic medical centers, and dedicated autism research programs. The core of their analysis focused on the genetic profiles of nearly 180,000 individuals who had undergone genetic testing and had a diagnosis of autism.
The scientific rigor of this study is underscored by its incorporation of data from ten distinct and reputable sources. These included major commercial genetic testing providers such as GeneDx, Labcorp, and Ambry Genetics, alongside large-scale research initiatives like the SPARK (Simons Foundation Powering Autism Research for Knowledge) study and the Autism Sequencing Consortium. Furthermore, data from several prominent children’s hospitals, crucial centers for diagnosing and managing developmental disorders, were integrated into the analysis.
By meticulously combining and analyzing this extensive dataset, the researchers were able to account for several critical factors that could influence prevalence estimates. These included the number of individuals with PMS who likely remain undiagnosed, inherent limitations in the sensitivity and scope of certain genetic testing methodologies, and the subset of individuals with PMS who do not exhibit characteristics that would lead to an autism diagnosis. After these adjustments, the study’s refined estimate places the prevalence of Phelan-McDermid syndrome at 13.7 cases per 100,000 individuals. This translates to an approximate prevalence of 1 in 7,300 people, a stark contrast to previous, more conservative estimates.
The implications of this revised figure are substantial. If the estimate holds true, it suggests that upwards of 45,000 people in the United States alone might be living with Phelan-McDermid syndrome without a formal diagnosis. This highlights a critical gap in identification and underscores the need for enhanced diagnostic efforts.
Addressing the Diagnostic Gap: Barriers and Solutions
Tess Levy, MSc, Assistant Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai, a certified genetic counselor at the Seaver Autism Center, and the first author of the published paper, offered critical insights into the reasons behind this significant discrepancy between known and estimated cases. "The large gap between known and estimated cases is likely due in large part to the fact that many individuals with developmental disabilities and autism are never offered genetic testing," Levy stated. She further elaborated on the systemic challenges, noting, "Families may also face insurance barriers or may receive tests that do not adequately evaluate the SHANK3 gene."
These barriers can create a cascade of missed opportunities. Without comprehensive genetic evaluation, individuals with PMS may be misdiagnosed or remain undiagnosed, preventing them from accessing crucial support services, appropriate therapies, and potentially life-changing clinical trials. The financial burden of genetic testing, often not fully covered by insurance, can be a significant hurdle for many families already navigating the complexities of raising a child with a developmental disability. Moreover, the specificity of genetic tests is paramount; if a test does not sufficiently probe the SHANK3 gene, it might fail to detect the underlying cause of PMS.
The Pivotal Role of Genetic Testing in Diagnosis and Treatment
The researchers strongly advocate for broader and more consistent access to genetic testing as a cornerstone for improving diagnostic rates and ultimately benefiting individuals with PMS. "We recommend that every child with autism undergo genetic testing, because knowledge is power," emphasized Joseph D. Buxbaum, PhD, Director of the Seaver Autism Center, a co-founder of the Autism Sequencing Consortium, and the senior author of the study. He elaborated on the transformative impact of genetic findings: "These genetic findings allow researchers to design more targeted clinical trials for potential therapies. I truly believe that within the next five years, we’ll see successful examples of new treatments coming from these genetic discoveries."
The push for universal genetic testing in children with autism is not merely about assigning a label; it’s about unlocking pathways to personalized medicine. When the underlying genetic cause of a developmental disorder is identified, it provides researchers with invaluable information about the biological mechanisms at play. This knowledge is essential for developing therapies that directly address the root cause of the condition, rather than just managing symptoms. The timeline Buxbaum suggests – the next five years – reflects the accelerating pace of research and development in the field of precision medicine, particularly for genetic disorders.
Industry and Advocacy Respond to the Emerging Landscape
The comprehensive nature of this PMS prevalence study, supported by grants from CureSHANK and Neuren Pharmaceuticals, has been widely acknowledged as a significant advancement in understanding the scope of the syndrome. Rachel Groth, PhD, Head of External Innovation and Patient Advocacy at Neuren Pharmaceuticals, highlighted the ethical imperative driving this research: "Neuren Pharmaceuticals initiated this landmark PMS prevalence study in collaboration with the Seaver Autism Center at Mount Sinai and CureSHANK because, with new treatments moving closer to reality, identifying these individuals has become an ethical imperative. Patients cannot benefit from these advances if they never receive a diagnosis." This statement underscores the critical link between diagnosis and access to novel therapeutic interventions.
A New Era of Treatments and Clinical Trials
The timing of these revised prevalence estimates is particularly opportune, coinciding with a surge of activity in Phelan-McDermid syndrome research. Several promising clinical trials are currently underway, exploring innovative, precision medicine approaches that target the specific biological pathways disrupted by the SHANK3 gene alteration. These trials represent a new frontier in treating genetic disorders, moving beyond symptom management to potentially disease-modifying interventions.
For individuals diagnosed with PMS and their families, a genetic diagnosis is increasingly becoming a gateway to a more comprehensive system of care and research participation. Beyond understanding the cause of their symptoms, a diagnosis can unlock access to specialized medical teams with expertise in PMS, opportunities to participate in cutting-edge research studies, enrollment in clinical trials for novel therapies, connections to supportive patient advocacy networks, and the potential to benefit from treatments that could fundamentally alter the course of the disorder.
Geraldine Bliss, Board Chair of CureSHANK, echoed the sentiment of many within the patient and advocacy community: "This study confirms what many families, clinicians, and advocates have suspected for years. There are likely tens of thousands of individuals with Phelan-McDermid syndrome who have never received a genetic diagnosis. At a time when multiple therapeutics are advancing into clinical trials, finding these individuals has never been more important." Her statement emphasizes the collective awareness within the community of the underdiagnosis issue and the urgency to connect individuals with emerging treatments.
The findings from the Mount Sinai study further bolster CureSHANK’s ongoing efforts to expand access to genetic testing. The organization actively champions initiatives like "Start Genetic," a global awareness campaign designed to encourage patients, families, healthcare providers, and advocacy groups to prioritize genetic testing as a first step in the diagnostic process. This campaign aims to shift the paradigm of diagnosis, ensuring that genetic evaluation is considered early and systematically.
Ultimately, the broader message resonating from this research is clear: the transformative potential of precision medicine in treating rare genetic disorders can only be fully realized if the individuals who could benefit from these advances are first identified and accurately diagnosed. The revised prevalence estimates for Phelan-McDermid syndrome serve as a powerful call to action, urging a concerted effort to bridge the diagnostic gap and ensure that every individual with PMS has the opportunity to access the care and therapies they deserve. The scientific community, in partnership with patient advocacy groups and pharmaceutical innovators, is poised to make significant strides in improving the lives of those affected by this complex syndrome.
